Non-Antimicrobial Adjuvant Therapy Using Ticagrelor Reduced Biofilm-Related Staphylococcus aureus Prosthetic Joint...

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Prosthetic joint infection (PJI), often caused by Staphylococcus aureus, is a major cause of arthroplasty failure.
• Staphylococcus aureus biofilms are key virulence factors in PJI, making infections resistant to antibiotics.
• Non-antibiotic adjuvants are being explored to enhance PJI treatment success.

Purpose of the Study:

• To investigate the anti-staphylococcal and antibiofilm activity of ticagrelor.
• To elucidate the molecular mechanisms behind ticagrelor's antibiofilm effects.
• To evaluate the efficacy of ticagrelor in treating Staphylococcus aureus PJI in an animal model.

Main Methods:

• In vitro assessment of ticagrelor's antibacterial and antibiofilm activity using broth microdilution and crystal violet staining.
• Analysis of ticagrelor's impact on Staphylococcus aureus biofilm gene expression (icaA, icaD, ebps, fib, eno, agr).
• In vivo evaluation in a mouse model of Staphylococcus aureus PJI, comparing ticagrelor alone, cefazolin alone, and combination therapy.

Main Results:

• Ticagrelor exhibited in vitro antibacterial and antibiofilm activity against Staphylococcus aureus.
• Ticagrelor downregulated key biofilm-related genes (fib, icaD, ebps, eno) in a strain-specific manner.
• In vivo, ticagrelor significantly reduced bacterial load on implants and dissemination to surrounding tissues in a PJI mouse model.

Conclusions:

• Ticagrelor shows promise as an adjuvant therapy for Staphylococcus aureus PJI, reducing infection burden in an animal model.
• The study provides preliminary evidence for ticagrelor's antibiofilm mechanisms.
• Further research is warranted to explore the clinical implications of ticagrelor for PJI treatment.